# US 4,391,803 A · Adrenosteriod composition and method for the treatment of shock by infusional therapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 4,391,803 A - Document ID: US4391803A - Status: Granted - Kind: A - Application number: 06/375,749 - Filed: 1982-05-06 - Granted: 1983-07-05 - Earliest claimed: 1982-04-05 - Assignees: Hepar Industries, Inc. - Inventors: Fernando F. Fussi - Web page: https://patentgrep.com/patent/US4391803A ## CPC - A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Septic shock and other forms of shock are effectively treated using a blend of 18 different adrenosteroids in their physiologic ratios based upon an animal cortex extract as a model. The blend preferably administered by infusion to a person suffering from shock. The blend is more effect and at a lower dosage level than hydrocortisone base or water-soluble derivatives of hydrocortisone. ## Claims ### Claim 1 A pharmaceutical composition consisting essentially, in percent by weight, of the following adrenosteroids: ______________________________________ 1. 11-Dehydrocorticosterone 10.0 .+-. 1.5 2. Corticosterone 18.5 .+-. 2.5 3. 11-Deoxy-17-hydroxycorticosterone 3.0 .+-. 0.5 4. Cortisone 14.0 .+-. 2.0 5. Hydrocortisone 23.0 .+-. 3.5 6. 4-Pregnene-5 and/or 20,21-diol or 2.0 .+-. 0.5 triol-3,11-dione 7. 4-Pregnene-5,17.alpha.,20.beta.,21-triol or 2.0 .+-. 0.5 tetrol-3,11-dione 8. 4-Pregnene-5,11.beta.,17.alpha.,20.beta.,21-tetrol-3-one 3.0 .+-. 0.5 9. 3.alpha. or .beta.,21-Dihydroxy-5.alpha. or .beta.-pregnane- 2.5 .+-. 0.5 11,20-dione 10. 3.alpha. or .beta.,11.beta.,21-Trihydroxy-5.alpha. or 3.0 .+-. 0.5 .beta.-pregnan-20-one 11. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnan-20-one 12. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.4 .+-. 0.5 .beta.-pregnane-11,20-dione 13. 3.alpha. or .beta.,17,21-Tetrahydroxy-20-oxo-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnane 14. Allopregnane-3.beta.,17.alpha.,20.beta.-21-tetrol 2.0 .+-. 0.5 15. Allopregnane-3.beta.,11.beta.,17.alpha.,20.beta.,21-pentol 2.0 .+-. 0.5 16. Deoxycorticosterone 3.0 .+-. 0.5 17. 18-Hydroxy-deoxycorticosterone 1.5 .+-. 0.3 18. Aldosterone 3.0 .+-. 0.5 ______________________________________ together with a pharmaceutically acceptable carrier or diluent. ### Claim 2 (depends on 1) The pharmaceutical composition as claimed in claim 1 in the form of parenteral solution. ### Claim 3 (depends on 1, 2) The pharmaceutical composition as claimed in claim 1 or 2 in the form of sterile, isotonic aqueous solution. ### Claim 4 (depends on 1, 2) The pharmaceutical composition as claimed in claim 1 or 2 in the form of an emulsion. ### Claim 5 (depends on 3) The sterile, isotonic aqueous solution as claimed in claim 3 containing about 0.06 percent by weight of the adrenosteroid composition. ### Claim 6 (depends on 4) The emulsion as claimed in claim 4 containing about 0.06 percent by weight of the adrenosteroid composition. ### Claim 7 (depends on 1) The pharmaceutical composition as claimed in claim 1 also including dextran, dextrose, glucose, plasma, amino acids, lipids or mixtures thereof. ### Claim 8 A method of treating the effects of shock comprising administering to a mammal suffering therefrom a symptom ameliorating amount of a pharmaceutical composition consisting essentially, in percent by weight of: ______________________________________ 1. 11-Dehydrocorticosterone 10.0 .+-. 1.5 2. Corticosterone 18.5 .+-. 2.5 3. 11-Deoxy-17-hydroxycorticosterone 3.0 .+-. 0.5 4. Cortisone 14.0 .+-. 2.0 5. Hydrocortisone 23.0 .+-. 3.5 6. 4-Pregnene-5 and/or 20,21-diol or 2.0 .+-. 0.5 triol-3,11-dione 7. 4-Pregnene-5,17.alpha.,20.beta.,21-triol or 2.0 .+-. 0.5 tetrol-3,11-dione 8. 4-Pregnene-5,11.beta.,17.alpha.,20.beta.,21-tetrol-3-one 3.0 .+-. 0.5 9. 3.alpha. or .beta.,21-Dihydroxy-5.alpha. or .beta.-pregnane- 2.5 .+-. 0.5 11,20-dione 10. 3.alpha. or .beta.,11 ,21-Trihydroxy-5.alpha. or 3.0 .+-. 0.5 .beta.-pregnan-20-one 11. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnan-20-one 12. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.4 .+-. 0.5 .beta.-pregnane-11,20-dione 13. 3.alpha. or .beta.,17,21-Tetrahydroxy-20-oxo-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnane 14. Allopregnane-3.beta.,17.alpha.,20.beta.-21-tetrol 2.0 .+-. 0.5 15. Allopregnane-3.beta.,11.beta.,17.alpha.,20.beta.,21-pentol 2.0 .+-. 0.5 16. Deoxycorticosterone 3.0 .+-. 0.5 17. 18-Hydroxy-deoxycorticosterone 1.5 .+-. 0.3 18. Aldosterone 3.0 .+-. 0.5 ______________________________________ ### Claim 9 (depends on 8) The method as claimed in claim 8 wherein the shock symptoms being treated are caused by septic shock, traumatic shock or the shock resulting from burns. ### Claim 10 (depends on 8, 9) The method as claimed in claim 8 or 9 wherein the pharmaceutical composition also includes dextran, dextrose, glucose, plasma, amino acids, lipids or mixtures thereof. ### Claim 11 (depends on 8) The method as claimed in claim 8 wherein the pharmaceutical composition is administered parentally to the mammal.